The combination of Bayer's mineralocorticoid receptor antagonist (MRA) finerenone and Boehringer Ingelheim and Eli Lilly's ...

It is the first fundraising effort at Neuralink since its $280 million Series D round in 2023 and brings the company's total ...

A long-acting medicine developed by Novo Nordisk has been recommended as a treatment option for young people with growth ...

In another sign of recovery in digital health investing, Omada Health has priced an initial public offering (IPO) of $19 per ...

The tantalising development has been reported by researchers at the Peter Doherty Institute for Infection and Immunity in ...

Added to that, 23andMe suffered a massive data breach in 2023 that resulted in information from about 7 million people being ...

"Calquence plus venetoclax is the first and only all-oral combination treatment option with a second-generation BTK inhibitor ...

Citylabs 4.0, now open in the heart of Manchester’s Knowledge Quarter on the Oxford Road Corridor, was built with exactly ...

The cash-based acquisition – the financial terms of which are not being disclosed – will expand Hims & Hers' presence in the ...

Zaynich is based on cefepime, a well-established beta-lactam antibiotic, combined with a novel beta-lactamase inhibitor ...

The conversation centred on the company’s latest developments and strategic direction in cancer therapies, with a particular ...

The FDA is moving at breakneck speed to roll out a generative artificial intelligence (AI) tool for speeding up regulatory ...